Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Mar 25, 2017 8:13am
103 Views
Post# 26029942

RE:RE:Zacks

RE:RE:Zacks1 - I try to post the honest truth (and sometime opinions). Unfortunately people don't like to hear the truth unless it's in line with their dreams. When I first read the zacks article I was super hyped. However in my last post I was just saying I was disappointed with the authors track record. Go look at all his 18 stocks he covers. Look at the date he initiated coverage and look at the stock price on that date and compare to today's stock price, very underwhelming.  I'm just saying I'm not putting as much stock in his review based on his track record. I do believe antibe is greatly undervalued. It is a little silly how people who post something that isn't viewed as 100% promotion must make them a basher.
2 - I've always been long on Antibe
3 - I post a lot of announcements, NR, etc as soon as they've come available. I've had many informative post although some days I get bored at work and yeah some of my posts probably aren't worth reading. Just escaping the corporate life for a bit.
4 - When it was 15 cents I said I wouldn't be surprised if it dipped to 0.12 because the low volume and limited exposure. I never said i thought it was worth that. I put in a stink bid at that price in case. I have been continually investing even after that. Still buying at 0.20. I'm glad it didn't dip.
5- I am already very profitable with Antibe and if i liquidated all now would make a sizeable profit.
6 - Yes I've made a few suggestions on what I think the stock was worth in the past with limited evidence to support it but I've always admitted to that. I've always stated it was just my opinion and only loosely based on my experience without  much to back it.
I didn't bother to do the exact math of my estimate and won't do it right now. But let's do a rough estimate, basically what I'm saying is Antibe is worth at minimum at least as much as they were worth back in 2014, probably twice that with  now. The max share price then was around 0.85, however that was only roughly 37 million shares (45 million fully diluted).  So let's say 37M share at 0.85 = 31.5 Million Market cap. I'm willing to say now that we have done this mini Phase 2 trial with success, one can easily argue we are twice as valuable as we were back in 2014. That would put us at 62.5M market cap. We have a share bases of 113M. That would put the stock price at roughly 0.56
Yes I admit this is simple calculation. Yes I admit Zacks evaluation is attractive. I simply stated he doesn't seem to have a great track record. I was surprised that after the article the price didn't really spike up. My only explanations I can come up with is that people are either not reading the report or not taking it seriously. Please feel free to suggest other ideas why this didn't gap up since that article?
 
Bullboard Posts